1	Identification of consensus head and neck cancer-associated microbiota signatures: a
2	meta-analysis of 16S rRNA and The Cancer Microbiome Atlas datasets.
3	Kenny Yeo ^{1,2} , Runhao Li ^{1,3} , Fangmeinuo Wu ^{1,3} , George Bouras ² , Linh T.H. Mai ^{1,2} , Eric
4	Smith ^{1,3} , Peter-John Wormald ^{1,2} , Rowan Valentine ² , Alkis James Psaltis ^{1,2} , Sarah Vreugde ^{1,2} ,
5	and Kevin Fenix ^{1,2}
6	(1) Discipline of Surgery, Adelaide Medical School, The University of Adelaide, Adelaide,
7	SA, 5000, Australia
8	(2) Department of Surgery- Otolaryngology Head and Neck Surgery, The University of
9	Adelaide and the Basil Hetzel Institute for Translational Health Research, Central Adelaide
10	Local Health Network, Adelaide, SA, 5000, Australia
11	(3) Department of Haematology and Oncology, Basil Hetzel Institute for Translational Health
12	Research and The Queen Elizabeth Hospital, Central Adelaide Local Health Network,
13	Adelaide, SA, 5000, Australia
14	
15	Corresponding author:
16	Kevin Fenix
17	Email: kevin.fenix@adelaide.edu.au
18	Word count: 6021
19	
20	
21	
22	
23	
24	
25	

Highlights: 26

Analysis

27	• The first meta-analysis of tissue microbiome in head and neck cancer containing eleven				
28	16S ribosomal RNA and The Cancer Microbiome Atlas dataset.				
29	• Microbiome from head and neck tissues were able to distinguish tissue types (cancer,				
30	cancer-adjacent, non-cancer) using 16S rRNA sequencing and whole genome sequencing				
31	datasets.				
32	• Specific bacterial genera correlate with different tumour microenvironment phenotypes.				
33	• High abundance <i>Fusobacterium</i> in tumour tissue correlates with better overall survival.				
34					
35	Abstract:				
36	Objective: Multiple reports have attempted to describe the tumour microbiota in head and				
37	neck cancer. However, these have failed to produce a consistent microbiota signature which				
38	may undermine understanding the importance of bacterial-mediated effects in head and neck				
39	cancer. The aim of this study is to consolidate these datasets and identify a consensus				
40	microbiota signature in head and neck cancer.				
41	Methods: We analysed 11 published head and neck cancer 16S ribosomal RNA microbial				
42	datasets collected from cancer, cancer-adjacent and non-cancer tissue to generate a consensus				
43	microbiota signature. These signatures were then validated using The Cancer Microbiome				
44	Atlas database.				
45	Results: We identified unique bacteria enrichment within tissue types and correlated it with				
46	possible functional and clinical outcomes.				
47	Conclusions: Our meta-analysis demonstrates a consensus microbiota signature for head and				
48	neck cancer, highlighting its potential importance in this disease.				
49					
50	Keywords: Tumour Microbiota, Head and Neck Cancer, 16s rRNA Sequencing, Meta-				
51	Analysis				

53 **1. Introduction**

54 Recent studies have revealed that cancers previously thought to be sterile can contain unique 55 microbial communities. The extent of microbial infiltration varies across different cancer 56 types, with head and neck cancers (HNSC) containing one of the highest level of intratumoral microbial infiltrates while glioblastomas having the least amount of microbes.¹⁻³ This 57 58 "intratumoral microbiota" can refer to bacterial infiltrates found in the extracellular matrix or within the cellular components of the tumour such as cancer, immune and stromal cells.² It is 59 60 now widely appreciated that intratumoral bacteria can have direct and indirect effects on tumours or the tumour microenvironment (TME).⁴⁻⁶ The presence of specific intratumoral 61 62 bacteria has been reported to influence multiple features of tumour biology including 63 treatment efficacy, local immune composition and activity and promoting tumour metastasis.7-10 64

65

66 Direct interaction between specific bacterial species with the tumour and the TME can induce 67 chemoresistance, promote tumour progression, enhance therapeutic responses and modulate anti-tumour immunity through various mechanisms.¹¹⁻¹⁴ Bacteria can metabolise an active 68 69 drug into its inactive form or induce autophagy in cancer cells which can promote chemoresistance.¹²⁻¹⁴ Moreover, specific bacterial species can mount or suppress anti-tumour 70 71 responses.¹⁵⁻¹⁷ Most notably, *Fusobacterium nucleatum* colocalises with cancer and immune 72 cells by binding to cell surface receptors such as Toll-like receptor 4 (TLR-4), T-cell 73 immunoreceptor with Ig and ITIM domains (TIGIT) and Carcinoembryonic Antigen-Related 74 Cell Adhesion Molecule 1 (CEACAM-1) receptors, or sugar groups (e.g. tumour expressed Galactose-N-acetylgalactosamine), which may then promote chemoresistance and suppress 75 anti-tumour immunity^{13, 15, 18-22}. Alternatively, *Bifidobacterium species* enhance anti-tumour 76 immunity and efficacy of PD-1 immunotherapy responses.^{8, 23, 24} 77

78

79 The release of bacterial metabolites such as short chain fatty acids (SCFA), amino acids, vitamins and bile acids can indirectly affect the tumour and the TME.^{25, 26} Butyrate, a SCFA 80 81 released by anaerobic bacteria through fermentation of carbohydrates, can decrease tumour cell growth and invasion, while increasing CD8⁺ T cell-mediated anti-tumour responses.²⁷⁻³⁰. 82 83 However, butyrate has also been shown to have pro-tumorigenic effects by inducing senescence-associated inflammatory phenotypes and inhibiting natural killer cell functions.³¹, 84 ³² Bacteria-derived indole and its derivatives (i.e. indole-3-lactic acid) have been shown to 85 86 suppress anti-tumour immunity by activating immunosuppressive tumour-associated 87 macrophages in treatment-naïve pancreatic cancer, while improving chemotherapeutic and immune-checkpoint inhibitor efficacy in pancreatic cancer and melanoma.³³⁻³⁵ Together, 88 89 these studies demonstrate that the tumour microbiota can influence cancer clinical outcomes 90 in a context-dependent manner.

91

There are multiple reports describing the microbiota in HNSC.³⁶⁻⁸⁹ Most of these studies 92 93 compared the microbiota diversity and bacterial relative abundance between cancer and healthy samples using 16S ribosomal RNA (rRNA) sequencing^{36-85, 88, 89}, while two studies 94 additionally correlated the impact of the microbiota with matched transcriptome analysis.^{86,90} 95 96 Samples studied include tissues, swabs, and oral fluids (saliva or oral rinse) from cancer and 97 healthy patients. Specifically for HNSC tissue microbiota analysis, samples included cancer, 98 cancer-adjacent (approximately > 5 mm away from the tumour), contralateral, and healthy donor tissue samples.^{36-55, 57-60, 85-89} Most bacteria identified in HNSC are oral commensal 99 100 bacteria from the genera Streptococcus, Rothia, Fusobacterium, Haemophilus and Prevotella.³⁶⁻³⁸ However, changes in microbial composition have been identified when cancer 101 102 samples are compared to healthy controls. In general, there was an enrichment in

103	<i>Fusobacterium</i> within cancer tissue samples, that correlated with an inflammatory
104	phenotype. ^{36, 37, 47} However, inconsistencies are observed for microbes such as <i>Streptococcus</i> ,
105	Actinomyces and Prevotella warranting the need to identify a consensus microbiota signature
106	for HNSC. ^{37, 38, 43, 54, 85}
107	
108	In this study, we systematically reviewed the literature and performed a meta-analysis to
109	consolidate the currently heterogenous HNSC-associated microbiota data. Selected 16s rRNA
110	sequencing datasets were analysed consistently to minimise variability between different
111	sample cohorts and adjusted for batch-effects. ⁹¹ These consensus HNSC-associated microbial
112	signatures were then validated using whole genome sequencing (WGS) data from The Cancer
113	Microbiome Atlas (TCMA). ¹ Finally, we correlated the presence of different microbiota

114 signatures with the HNSC tumour microenvironment and clinical outcomes.

115 **2. Methods**

- 116 This study was performed according to the Preferred Reporting Items for Systematic Reviews
- 117 and Meta-Analyses (PRISMA) Statement.⁹²

118 2.1 Search and Study Selection

- 119 The following criteria were used to select datasets: 1) Tissue samples, 2) Presence of
- 120 metadata to distinguish sample types, 3) Illumina short-read amplicon sequencing of 16S
- 121 rRNA V3 to V5 primers (Figure 1). Database search was performed on 16 August 2022 and
- 122 datasets after this date were not included (Supplementary Table 1). The risk of biasness
- 123 assessment was conducted using RoB 2 (β v9) (Supplementary Table 1).
- 124 125
- Pubmed 104 articles retrieved Identification and screening Excluded (n = 68) Review articles (n = 2) Inclusion of 1 Title and/or abstracts not relevant to dataset found selection topic or criteria (n = 65) from SRA not Correction paper (n =1) linked to published papers Pubmed 36 articles remaining and 1 SRA project accession Excluded (n = 26) No project accession number or incomplete data (n = 8) Eligibility Assessment No metadata to distinguish samples (n = 1) Incomplete data uploaded (n = 1) Different sequencing techniques (n = 12) Non-tissue samples (n = 3) No sequencing data (n = 1) Pubmed 10 articles remaining and 1 SRA project accession Inclusion Pubmed 10 articles remaining and 1 SRA project accession (Total = 11 SRA project accession) Figure 1: Study selection flow chart.
- 128 129

131 Previously published raw sequences were retrieved from the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA) using pysradb.⁹³ Samples 132 133 were divided into three main groups - cancer, cancer-adjacent and non-cancer tissues. Cancer 134 tissues are defined as tissues obtained directly from the tumour, while cancer-adjacent tissues 135 are cancer-free regions obtained > 5mm away from cancer tissues. Non-cancer tissues are 136 defined as tissues that were either obtained from healthy patients or contralateral tissues 137 obtained from cancer patients. FASTQ sequences files were obtained from SRA using 138 sratoolkit.⁹⁴ These sequences were processed using OIIME2 DADA2 denoise-paired and 139 reads truncated using the same parameters (trim left f = 30, trim left r = 30, trunc q = 15). 140 Sequences from different studies were merged before bacterial Operational Taxonomic Units 141 (OTU) classification using QIIME2 and SILVA reference database (version silva-138-99-nbclassifier).⁹⁵ 142

143

144 Raw microbial reads were filtered, central log-ratio (CLR) transformed and batch-adjusted using Phyloseq and MixOmics as described previously.⁹⁶⁻⁹⁸ Microbiome datasets are 145 146 inherently compositional, hence, CLR transformation addresses generates scale-invariant 147 values which allows datasets to remain unaffected by variations in library sizes among samples.⁹⁹ Briefly, low abundance of OTUs were filtered through proportional counts of all 148 149 samples (< 1%) and minimum counts per sample (< 10). Bacterial OTUs were agglomerated 150 at the genus level before transforming into CLR for their compositional nature.^{96, 98} The CLR-151 abundance was used for subsequent statistical and discriminant analysis. A total of 903 SRA 152 samples from 11 projects were downloaded (Table 1).

- 153
- 154
- 155
- 156

157

160	Accession number	Sample size			Primers
161		Cancer	Cancer- adjacent	Non-cancer	
101	PRJNA412445	16	0	0	V4 -V5
1.60	PRJNA555458	0	0	4	V3 -V4
162	PRJNA596113	102	53	0	V3 -V4
	PRJNA597251	19	20	0	V3 -V4
163	PRJNA666746	50	50	0	V3 -V4
	PRJNA666891	7	0	10	V4
164	PRJNA685226	13	13	0	V3 -V4
	PRJNA699728	37	0	201	V4
165	PRJNA803155	40	0	0	V4 -V5
	PRJNA822685	75	79	0	V3 -V4
166	PRJNA866676	37	36	41	V3 -V4

158 Table 1: Study accession and sample size post-filtering159

167

168 2.3 Discriminant analysis of 16S rRNA dataset

169 To discriminate the microbial signature between sample types, we employed both 170 multivariate and univariate discriminant analysis. For β -diversity analysis, CLR-abundance of 171 all genera were ordinated using Euclidean distance and plotted on a principal component 172 analysis (PCA) using mixOmics R package. β -diversity for each sample were calculated as 173 distance to centroid for each tissue groups using betadisper (vegan v2.6-4). Group and 174 pairwise permutest (vegan v2.6-4, permutations = 9999) was performed to determine if 175 dispersions differed between sample types, while group and pairwise permutational 176 multivariate analysis of variance (PERMANOVA) was performed using adonis2 (vegan v2.6-177 4, method = "euclidean", permutation = 9999) and pairwise.adonis2 (pairwiseAdonis, method 178 = "euclidean", permutation = 9999) to determine statistical differences in β -diversity between 179 groups. Other statistical test such as Analysis of similarities (ANOSIM) (vegan v2.6-4, 180 distance = "euclidean", permutation = 9999) and Fifty-fifty multivariate analysis of variance 181 (FFMANOVA) (nSim = 9999) were also applied as supplementary to distinguish between sample types.^{100, 101} 182

183 Multivariate sparse partial linear discriminant analysis (sPLS-DA) was applied on batchadjusted dataset to identify discriminating genera within each sample type.⁹⁶ The Area Under 184 185 Curve (AUC) of the Receiver Operating Characteristics (ROC) curve was calculated using mixOmics in Rstudio.^{96, 98} The AUC value served as a quantification of the discriminatory 186 187 potential between sample types. A higher AUC value, closer to 1, signified a test approaching 188 perfection in its ability to distinguish between the samples. Heatmap of all representative 189 bacteria in each sPLS-DA was presented with sample type clustered according to Euclidean 190 distance and Ward's linkage.

191

Univariate Kruskal-Wallis test with Bonferroni multiple comparisons test was also performed to determine microbial genera differences between sample types using microbiomeMarker in Rstudio v3.3.0, followed by a post-hoc Wilcoxon test (Mann-Whitney test) with Bonferroni-Dunn multiple comparison test to determine differences between groups (cancer– canceradjacent, cancer – non-cancer, non-cancer – cancer-adjacent). Additionally, Wilcoxon matched-pairs signed rank test with Bonferroni-Dunn multiple comparison test was also performed on paired cancer and cancer-adjacent samples.

199

200 **2.4 Functional profiling analysis of 16S rRNA datasets in different sample types**

To predict the microbial functions of genera detected from 16S rRNA sequencing between each tissue sample type, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUST2) from QIIME2 was applied on raw 16S rRNA reads using MetaCyc database.^{102, 103} Functional abundance was processed and analysed similarly as described for raw microbial reads. Univariate Kruskal-Wallis test and post-hoc Wilcoxon test was performed as previously described to compare differences between groups.

208 2.5 Reanalysis of tissue microbiome data from TCMA

209 Decontaminated microbial read count derived from The Cancer Genome Atlas (TCGA) 210 HNSC whole genome sequences were obtained from TCMA repository.¹ Data from a total of 211 177 cancer (TCGA annotation: primary tumour) and 22 cancer-adjacent (TCGA annotation: 212 solid tumour normal) tissues were obtained from TCMA repository (n = 22 paired cancer and 213 cancer-adjacent samples). Similar to 16S rRNA pre-processing, read counts were 214 agglomerated to the genus before CLR transformation as described in 2.2. As samples were 215 already pre-processed in the TCMA dataset, no further filtering or batch adjustment was 216 required. Microbiome statistical analysis were performed similarly as 16S sequencing datasets. Metadata were obtained from cBioPortal for Cancer Genomics.¹⁰⁴ 217

218

219 2.6 Microbiome correlation analysis with tumour microenvironment and survival 220 analysis

221 The TME immune subtype and 29 functional gene expression signatures (FGES) scores were previously described by Bagaev et al. (2021) using transcriptomics datasets from TCGA.¹⁰⁵ 222 223 The 29 FGES represents the major functional components and immune, stromal, and other cellular populations of the tumour.¹⁰⁵ Pearson's correlation test was applied to determine the 224 225 correlation between FGES scores and selected bacteria genera. The four TME immune 226 subtypes were – Desert (D), Fibrotic (F), Immune-enriched (IE), Immune-enriched/Fibrotic (IE/F) (Described in Supplementary Table 2).¹⁰⁵ Specifically, tissues with IE and IE/F 227 228 phenotype contains high T-cell infiltration, while D and F phenotypes have low T-cell infiltration (Supplementary Table 2).¹⁰⁵ Using a cut-off of high (top 35th percentile) and low 229 230 (bottom 35th percentile) CLR-abundance, the proportion of each patient within the four TME 231 subtypes were determined, and survival analysis was performed. Since there were 153 232 TCGA-HNSC samples with both FGES/TME subtypes and microbiome datasets, these

233	samples were used for subsequent correlation and survival analysis. Chi-squared (χ^2) test was
234	performed in Prism9 to determine association between high/low bacterial genera CLR-
235	abundance and proportion of patients within each tumour subtype.

236

237

238

239 2.7 Statistical analysis

240 For comparisons made between all unpaired tissue groups, Kruskal-Wallis test with 241 Bonferroni's multiple comparison was used for comparisons made between all tissue groups 242 unless stated otherwise. Post hoc Wilcoxon matched pairs signed rank test with Bonferroni's 243 multiple comparison was used to compare differences between unpaired tissue samples. For 244 all paired cancer and cancer-adjacent samples, Wilcoxon matched-pairs signed rank test was 245 performed. Univariate and multivariate Cox proportional hazard model was performed using 246 survminer in Rstudio v3.3.0. Statistical analysis was performed using RStudio v3.3.0 and 247 Prism9.

249 **3 Results**

3.1 Multivariate analysis identifies homogenous microbial abundance and functions between cancer and cancer-adjacent samples, contrasting to non-cancer samples.

252 The 16S rRNA amplicon datasets were obtained for 903 head and neck tissue types (396 cancer, 251 cancer-adjacent, and 256 non-cancer) from 11 studies.^{37, 38, 41-45, 87-89} Following 253 254 sample processing and aggregation of 16S data at the genus level, a total of 177 distinct 255 bacterial genera were identified. Differences in the microbiota and β -diversity between tissue 256 types were assessed using PCA and PERMANOVA test (Figure 2A-2B). The β -diversity 257 index was calculated for cancer (14.6 \pm 5.7) and cancer-adjacent (15.0 \pm 5.5) tissues, 258 revealing similar levels of β -diversity. In contrast, non-cancer tissues (8.61 ± 5.3) exhibited 259 lower β -diversity (PERMANOVA – Overall R2 = 0.006, p < 0.0001) (Figure 2B). Post-hoc 260 pairwise test identified significant differences in β -diversity between cancer and non-cancer $(R^2 = 0.003, p = 0.002)$, cancer and cancer-adjacent $(R^2 = 0.005, p < 0.001)$, and non-cancer 261 and cancer-adjacent samples ($R^2 = 0.007$, p < 0.001) (Figure 2B). These findings were 262 263 consistent with additional multivariate and univariate statistical analysis, ANOSIM (R =264 0.027, p = 0.002) and FFMANOVA (p < 0.0001) (Supplementary Table 3).

265

Multivariate sparse partial least squares discriminant analysis (sPLS-DA) identified 116 representative bacterial genera in sPLS-DA component 1 and 2 which were discriminant between tissue types (Figure 2C-E). The AUC values were computed for different sample comparisons: cancer versus others (AUC = 0.74, p < 0.05), non-cancer versus others (AUC = 0.91, p < 0.05), and cancer-adjacent versus others (AUC = 0.84, p < 0.05). These results demonstrate that sPLS-DA components 1 and 2 (Figure 2D) can effectively differentiate between tissue types. Lastly, majority of cancer and cancer-adjacent samples clustered

273 together and were distinct from non-cancer samples, as determined by Euclidean distance

274 metric (Figure 2E).

275



276 Figure 2: Multivariate discriminant analysis (sPLS-DA and PERMANOVA) of tissue 277 16S rRNA microbiota to discriminant between cancer, cancer-adjacent and non-cancer 278 tissues. (A) Principal coordinates analysis (PCA) plot of tissue CLR-abundance microbiota 279 based on Euclidean distance. (B) Dispersion of β -diversity (top-right panel) for each sample 280 type, with error bar representing 95% confidence interval. PERMANOVA test was 281 performed with bacterial genera as variable for sample types. (C) sPLS-DA sample plot of 282 16S rRNA tissue microbiota. Ellipse displays 95% confidence interval for each sample group. 283 The batch-adjusted normalized abundance of tissue microbiota from 16S amplicon 284 sequencing was compared between cancer, cancer-adjacent and non-cancer tissue samples. 285 sPLS-DA identified 116 bacterial genera on component 1 and 2. (D) ROC curve and AUC 286 values determined from sPLS-DA analysis was used to access discriminatory potential of 287 sPLS-DA component 1 and 2. (E) Heatmap representing 86 bacterial genera after sPLS-DA 288 discriminant analysis. Each column and row represent a unique sample and bacterial genera 289 respectively, with OTUs clustered based on Euclidean distance and Ward linkage method.

290

3.2 Univariate analysis identifies differences in microbial abundance and functions between sample types.

293 Next, unpaired univariate analysis was applied to determine the differences between tissue 294 types. Out of the 177 bacterial genera, 33 were identified as significantly different among 295 tissue types using Kruskal-Wallis test ($P_{adjust} < 0.05$) (Supplementary Table 4). Notably, 18 of 296 these were also identified as representative bacterial genera in sPLS-DA discriminant 297 analysis (Supplementary Table 4). These 33 genera are denoted as bacterial genera of interest 298 (Supplementary Table 4). The top 20 differentially abundant genera, based on the effect size 299 (η^2) , are presented in Figure 3. Post-hoc unpaired Wilcoxon test with Bonferroni-Dunn's 300 multiple comparison test was performed on these genera to determine the mean differences in 301 the central log ratio transform (CLR) abundance between tissue types (Figure 3A,

302 Supplementary Table 5). Since most published studies compared cancer to non-cancer, or 303 cancer to cancer-adjacent tissues, we performed post-hoc test for these comparisons (Figure 304 3B). We identified 27 out of 33 genera as significantly different (P_{adjust} (#) < 0.05) between 305 cancer and non-cancer tissues (Figure 3A-3B, Supplementary Table 5). Non-cancer tissues 306 contained more *Fretibacterium* (CLR-abundance diff. = 1.42, SE = 0.12), *Stenotrophomonas* 307 (CLR-abundance diff. = 0.80, SE = 0.12) and *Tannerella* (CLR-abundance diff. = 0.71, SE = 308 0.10), while cancer tissue had a greater CLR-abundance of Neisseria (CLR-abundance diff. = 309 2.32, SE = 0.15), Capnocytophaga (CLR-abundance diff. = 2.02, SE = 0.15), and 310 Streptococcus (CLR-abundance diff. = 1.98, SE = 0.19) (Figure 3A-3B). Capnocytophaga abundance in cancer tissues was consistent to previous findings^{46, 57, 85}, while contradicting 311 findings were identified for the abundance for Streptococcus^{38, 41, 52, 57, 85} and 312 Fusobacterium^{38, 41, 42, 52, 57, 58}. 313

314

315 For cancer and cancer-adjacent tissue, 13 out of 33 bacterial genera were significantly 316 different (post-hoc unpaired Wilcoxon test P_{adjust} (*) < 0.05) (Figure 3A and 3C, 317 Supplementary Table 5). Similar to many studies, *Fusobacterium* (CLR-abundance diff. = 318 1.11, SE = 0.20) displayed significantly higher CLR-abundance in cancer tissue than cancer-319 adjacent tissue, while Rothia (CLR-abundance diff. = 0.92, SE = 0.18), Stenotrophomonas 320 (CLR-abundance diff. = 1.33, SE = 0.15) and Serratia (CLR-abundance diff. = 0.70, SE = 321 0.12) had higher CLR-abundances in cancer-adjacent tissue than cancer tissue (Figure 3A).³⁶, 37, 43, 45, 52, 55, 58, 59. Additionally, we found that *Prevotella* was elevated in cancer tissue as 322 compared to cancer-adjacent tissues.^{43, 45, 52, 55, 58} Unlike previous studies, we did not observe 323 324 any significant differences in Streptococcus abundance between cancer and cancer-adjacent tissues. 36, 37, 45, 51, 52, 55, 59 325

Lastly, 28 of the 33 top bacterial genera were significantly different (post-hoc unpaired Wilcoxon test $P_{adjust} < 0.05$) when comparing non-cancer to cancer-adjacent tissue samples (Figure 3A, Supplementary Table 5). Genera *Neisseria* (CLR-abundance diff. = 2.83, SE = 0.19), *Rothia* (CLR-abundance diff. = 1.95, SE = 0.16) and *Streptococcus* (CLR-abundance diff. = 1.95, SE = 0.16) were higher in CLR-abundance in cancer-adjacent, while *Fusobacterium* (CLR-abundance diff. = 1.80, SE = 0.18) and *Prevotella* (CLR-abundance diff. = 1.28, SE = 0.20 were greater in CLR-abundance in non-cancer tissue (Figure 3A).

335 To provide functional insights to microbial abundance between cancer tissues and other tissue 336 types, we applied Picrust2 to predict possible differences in MetaCyc pathway functional CLR-abundance.¹⁰² After filtering low abundant functional pathways, we identified a total of 337 338 365 MetaCyc pathways. Using Kruskal-Wallis test, 162 MetaCyc pathways were identified 339 as significantly different among sample types ($P_{adjust} < 0.05$) (Supplementary Table 5). Post-340 hoc analysis identified 129/162 and 7/162 pathways that were significantly different between 341 cancer – non-cancer, and cancer – cancer-adjacent tissues comparisons respectively 342 (Supplementary Table 6).

343

344 Cancer tissues, when compared to non-cancer tissues, were enriched in pathways involving 345 the synthesis of ubiquinol, L-methionine, inosine-5'-phosphate and cysteine and metabolic 346 pathways such as TCA cycle and pentose phosphate pathway, while non-cancer tissues were 347 enriched in the degradation of L-lysine, L-glutamine, N-Acetylglucosamine (GlcNac), N-348 acetylmannosamine (ManNac), and N-acetylneuraminate (Figure 3C). Cancer tissues were 349 more similar to cancer-adjacent tissues, albeit enrichment was identified in pathways 350 involving biosynthesis of ppGpp (guanosine pentaphosphate and tetraphosphate), cis-351 vaccenate, L-asparatate, L-asparagine, cob(II)yrinate a,c-diamide and CMP-legionaminate,

352 and enrichment in pathways involving degradation of pyruvate and L-lysine, when compared

353 to cancer-adjacent tissues (Figure 3C).



355 Figure 3. Comparison of bacterial CLR-abundance and functional prediction between

356 sample types. (A) Top 20 bacterial genera (based on effect size) in CLR-normalized 357 abundances between sample groups using Kruskal-Wallis test with Bonferroni's multiple 358 comparison. 33 out of 177 genera were identified as significantly different ($P_{adjust} < 0.05$) 359 using Kruskal-Wallis test. Post-hoc Wilcoxon test with Bonferroni-Dunn's multiple 360 comparison was performed to identify group-wise differences between Cancer - Non-cancer 361 (#), Cancer - Cancer-adjacent (*), Non-cancer - Cancer-adjacent (^). Post-hoc unpaired 362 Wilcoxon test with Bonferroni-Dunn's multiple comparison for (B) bacterial genera and (C) 363 functional CLR-abundance for Cancer – Non-cancer (Top panel), and Cancer – Cancer-364 adjacent (Bottom panel).

365

366 3.3 Paired cancer and cancer-adjacent tissues display similar bacterial abundance 367 differences using multiple sequencing techniques.

To understand microbial abundance differences between cancer tissue and cancer-adjacent tissue within the same patients, we performed Wilcoxon matched-pairs signed rank test to identify changes in microbial diversity and abundance within paired tissue samples in the 16S rRNA datasets. Similar to unpaired data analysis, no significant differences in microbial β diversity was identified between the patient's paired cancer and cancer-adjacent tissues (Supplementary Figure 2).

However, 76 bacterial genera were significantly different between paired tissue samples (Figure 4A, Supplementary Table 7). Bacterial genera with the greatest differences in CLRabundance were then identified by using a cut-off of > 0.4 and < -0.4 (Figure 3A). Using this cut-off, we found that *Fusobacterium, Prevotella, Alloprevotella, Catonella, Selenomonas and Treponema* were elevated in cancer tissue vs cancer-adjacent tissue, while *Stenotrophomonas, Rothia, Granulicatella, Serratia, Anoxybacillus, Actinomyces and*

Bacteroides were greater in cancer-adjacent tissue compared to cancer tissue (Figure 4A-4B). Similarly, nine of these bacteria were also found to be significantly different in unpaired tissue analysis (Supplementary Table 4 and 7). Contrary to published studies on unpaired samples, *Streptococcus*, an abundant oral commensal, was not significantly different in our paired sample analysis.^{36, 37, 45, 51, 52, 55, 59}

385 To validate this finding, we probed the publicly available TCMA dataset, a repository containing microbiota reads derived from WGS of tissue samples.¹ Similar to the 16S rRNA 386 387 dataset, we observed that cancer tissues from TCMA displayed significantly (p < 0.05) higher 388 CLR-abundance for genera Fusobacterium, Selenomonas and Treponema, while Rothia and 389 Actinomyces were elevated (p < 0.05) in cancer-adjacent tissues (Figure 4D). In the TCMA 390 dataset, Anoxybacillus, Serratia, and Stenotrophomonas were not present due to pre-analysis 391 filtering, while no significant differences in CLR-abundance were observed for *Prevotella*, 392 Catonella, Alloprevotella, and Bacteroides (Figure 4C). Notably, similar trend in CLR-393 abundance between cancer and cancer-adjacent samples was still observed for Prevotella, 394 Catonella, and Alloprevotella in TCMA dataset. Overall, 16S rRNA and TCMA WGS 395 dataset showed similar trend for most bacteria genera, regardless of sequencing techniques.



Figure 4: Comparison of tissue microbiota in paired cancer and cancer-adjacent tissue samples using different sequencing datasets. (A) Paired Wilcoxon matched-pairs signed rank test on paired 16S rRNA sequencing cancer and cancer-adjacent tissue samples. 76 bacteria were significantly different in sample groups (p < 0.05) using paired Wilcoxon matched-pairs signed rank test and 13 bacteria genera were identified as top bacteria with

402 differential CLR-abundance (Diff. CLR-abundance > 0.4 or < -0.4). Blue and red dot points 403 represent bacteria that were higher in abundance in cancer and cancer-adjacent tissues 404 respectively. CLR-abundance of paired cancer and cancer-adjacent samples from (**B**) 16s 405 rRNA sequencing and (**C**) TCMA WGS sequencing datasets. Wilcoxon matched pairs signed 406 rank test was performed for both 16s rRNA (n = 287) and TCMA (n = 22) datasets. *p < 407 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

408

3.4 Tissue microbiota diversity correlates with cancer functional gene expression signatures.

411 Since Fusobacterium, Selenomonas, Treponema, Actinomyces, and Rothia displayed 412 significant differences between paired cancer and cancer-adjacent tissues, we performed 413 correlation analyses to investigate the possible relationship between these genera and the 414 tumour transcriptional profile and patient clinical features found in matched TCGA patients (n = 156).¹⁰⁵ Here, TCGA transcriptomic data were classified into 29 functional gene 415 416 expression signatures (FGES), which represent major functional components and characteristics of cancer cell populations.¹⁰⁵ These 29 FGES can then be used to further 417 418 classify cancers into four major immune subtypes (Desert, Fibrotic, Immune-enriched/nonfibrotic, and Immune-enriched/fibrotic).¹⁰⁵ We correlated the CLR-abundance of 419 420 Fusobacterium, Selenomonas, Treponema, Actinomyces, and Rothia from TCGA-HNSC 421 patients with their respective FGES scores and immune subtype.

422

423 We first correlated CLR-abundance with the FGE signatures. The CLR-abundance of 424 *Fusobacterium* correlated (r > 0.3, p < 0.0001) with FGES related to angiogenesis, 425 neutrophils and granulocyte traffic (Figure 5A). Other FGES such as matrix remodelling, 426 protumour cytokines, MDSC traffic, M1 signature, antitumour cytokine, MHCI and EMT

427 signatures also positively correlated (p < 0.05) to CLR-abundance of *Fusobacterium* (Figure 428 5A). The CLR-abundance of *Selenomonas* showed a positive correlation (p < 0.05) to 429 angiogenesis, neutrophil signature, granulocyte traffic and antitumour cytokines signatures, 430 while negatively correlating (p < 0.05) to B cells (Figure 4A). Lastly, CLR-abundance of 431 Treponema displayed a negative correlation (p < 0.05) to endothelium, T reg traffic, T reg, 432 MHCII, Coactivation molecules, B cells, NK cells, Effector cells and T cells, while positively 433 correlating to (p < 0.05) neutrophils and granulocyte traffic (Figure 5A).

434

435 Next, we investigated how CLR-abundance correlated to tissue immune subtyping. Cancer 436 tissues classified as immune deserts (D) and fibrotic (F) which lack immune cell enrichment 437 correlated with higher Fusobacterium and Treponema CLR-abundance. On the other hand, 438 cancer tissues that are immune-enriched / non-fibrotic (IE) or immune-enriched / fibrotic 439 (IE/F) correlated with greater *Rothia*. No significant correlation in immune subtypes were 440 observed for Selenomonas and Actinomyces (Figure 5B). To identify the differences in 441 immune subtypes between high and low CLR-abundance of each bacterial genera, we further 442 segregated patients based on the upper and lower 35% CLR-abundance quartiles. As 443 expected, patients with IE and IE/F tumour subtypes showed significant association with low 444 CLR-abundance of *Fusobacterium* (chi-square test, p = 0.04). While not reaching statistical 445 significance, more patients with IE and IE/F tumour subtypes have low CLR-abundance of 446 Selenomonas (chi-square test, p = 0.33) and Treponema (chi-square test, p = 0.11), opposite 447 to high CLR-abundance for *Rothia* (Figure 5C). Conversely, patients with D and F subtypes 448 had higher CLR-abundance of *Fusobacterium*, Selenomonas or Treponema (Figure 5C). 449 Lastly, the proportion of patients in each immune subtype were similar in high and low CLR-450 abundance Actinomyces groups. Taken together, these show that Fusobacterium,

- 451 Selenomonas or Treponema are associated with poor T-cell infiltration compared to Rothia
- 452 which may have implications in selecting patients suitable for immunotherapy.



453

454 Figure 5: Correlation analysis of *Fusobacterium*, *Selenomonas*, *Treponema*, *Rothia*455 and *Actinomyces* to the tumour transcriptional profiles.

456 (A) 29 functional gene expression (FGES) signature scores derived from Bagaev et al 457 (2021) were used to correlated with CLR-abundance of genera *Fusobacterium*, 458 *Selenomonas, Treponema, Actinomyces, and Rothia,* using Pearson's correlation 459 method. Asterisk (*) represents significant correlation (p < 0.05), and red and blue

460 scales represents positive and negative correlation respectively. (B) The CLR-461 abundance of each bacterial genera within each tumour microenvironment immune 462 subtype (D – Desert, F – Fibrotic, IE – Immune-enriched/Non-fibrotic, IE/F – Immune-463 enriched/Fibrotic). Kruskal-Wallis test with uncorrected Dunn's test was performed to 464 compare CLR-abundance in all immune groups. p < 0.05, p < 0.01. (C) The 465 proportion of patients in each tumour immune subtype with high and low CLR-466 abundance in each bacterial genera. High and low bacteria CLR-abundance groups 467 were determined by upper and lower 35% quartiles respectively. Chi-squared test was 468 performed to determine association between high/low bacterial genera CLR-abundance 469 and proportion of patients in each tumour subtype.

470

471 **3.5** Evaluation of microbiota abundance with clinical features and survival

472 Univariate and multivariate Cox proportional hazard models were used to investigate the 473 association between the intratumoral microbiota and clinical features. Univariate Cox 474 proportional hazard model identified that current smokers (HR 2.235, 95% CI 1.146 – 4.359, 475 p = 0.018, HPV-negative (HR 2.273, 95% CI 1.158 – 4.459, p = 0.017), and low CLR-476 abundance of *Fusobacterium* (HR 0.8883, 95% CI 0.8183 - 0.9642, p = 0.005) were risk 477 factors for reduced overall survival (Table 2). Further multivariate Cox proportional hazard 478 models identified that HPV-negative (HR 2.853, 95% CI 1.1991 – 6.7882, p = 0.0178) and 479 low CLR-abundance of Fusobacterium (Continuous: HR 0.8482, 95% CI 0.7758–0.9273, p 480 = 0.0003; Low: HR 2.579, 95% CI 1.3687 - 4.860, p = 0.0034) were independent hazards for 481 overall survival, but not current smokers (Table 2).

- 482
- 483
- 484

			Univariate		Multivariable		
		n	HR (95% CI)	p-value	HR (95% CI)	p-value	
	< 65	106					
Age (years)	≥ 65	47	0.9832 (0.594 - 1.626)	0.947			
Sov	Female	41					
Sex	Male	112	0.868 (0.525 - 1.436)	0.581			
	Ι	4					
Staging	II	30	2.331 (0.302 - 17.97)	0.417			
Staging	III	31	2.275 (0.2950 - 17.54)	0.430			
	IV	87	3.275 (0.4492 - 23.87)	0.242			
	Positive	37					
HPV status	Negative	107	2.273 (1.158 - 4.459)	0.017*	2.853 (1.1991 - 6.7882)	0.0178*	
	Non-smoker	37					
Smoking	Current	43	2.235 (1.146 - 4.359)	0.018*	1.3788 (0.5383 - 3.5317)	0.50329	
	Previous	71	1.488 (0.7804 - 2.838)	0.227	0.7821 (0.3130 - 1.9545)	0.59894	
	Continuous	153	0.8883 (0.8183 - 0.9642)	0.005**	0.8482 (0.7758-0.9273)	0.0003**	
E h							
Fusobacterium	High	53					
	Low	53	2.0592 (1.17 - 3.625)	0.0123*	2.579 (1.3687 - 4.860)	0.0034*	
	Continuous		0.9712 (0.8714 -1.082)	0.597			
Selenomonas							
Selenomonas	High	53					
	Low	52	1.205 (0.7094 - 2.048)	0.49			
	Continuous	153	0.9467 (0.8768 – 0.719)	0.162			
Treponema							
теронени	High	53					
	Low	53	1.432 (0.8092 - 2.535)	0.217			
	Continuous	153	1.029 (0.8936 – 1.184)	0.694			
Rothia							
	High	54		o			
	Low	54	0.6552 (0.3585 - 1.198)	0.17			
	Continuous	153	0.9652 (0.8512 – 1.094)	0.58			
Actinomyces	TT' 1	52					
-	High	53	1.000 (0.5070 1.702)	0.002			
	LOW	52	1.006 (0.5679 – 1.783)	0.983			

485 Table 2: Univariate and multivariable Cox pr	roportional hazard models for overall survival
--	--

487 **4 Discussion:**

488 Several studies have investigated the microbial signature in HNSC using different sequencing 489 approaches and sample types, such as tissues, swabs, and oral fluids. However, these studies 490 have reported inconsistent findings regarding the presence of specific bacterial genera. 491 Consequently, a consensus microbial signature for head and neck tissues has yet to be 492 established. In this study, we aimed to address this gap by conducting a meta-analysis of 11 493 studies and presenting a consensus tissue microbiota signature for head and neck tissues. We 494 analyzed 16S rRNA sequencing datasets from 903 tissue samples, including 396 cancer 495 tissues, 251 cancer-adjacent tissues, and 256 non-cancer tissues. Our analysis revealed 496 significant differences in the abundance of 33 bacterial genera among the various tissue 497 types. Specifically, we observed that cancer tissues and cancer-adjacent tissues exhibited 498 greater similarity to each other compared to non-cancer tissues. These findings suggest 499 distinct microbial profiles in cancer and cancer-adjacent tissues compared to non-cancer 500 tissues. Non-cancer tissues exhibited the lowest differences in β -diversity and contained 501 elevated levels of bacterial genera such as Tannerella, Fretibacterium, Stenotrophomonas, 502 Fusobacterium, and Prevotella (Figure 6A). While cancer and cancer-adjacent tissues 503 displayed similar microbiota based on β -diversity indexes, further analysis using paired and 504 unpaired univariate methods enabled differentiation of these tissues at the genera level 505 (Figure 6B). Importantly, these abundance signatures were validated using additional data 506 from TCMA. Matching TCMA samples with transcriptomic data derived from TCGA) and 507 clinical features provided insights into the contributions of individual genera in HNSC. 508 Notably, we found that a high abundance of *Fusobacterium* was associated with better overall 509 survival in HNSC patients Overall, our study contributes to the establishment of a consensus 510 tissue microbiota signature for HNSC, shedding light on the distinct microbial profiles in 511 different tissue types and their potential implications for clinical outcomes.





513 Figure 6: Summary of bacteria genera within cancer, cancer-adjacent and non-cancer 514 tissue samples. (A) Elevated microbiota within non-cancer tissues compared to cancer and 515 cancer-adjacent tissues. (B) Elevated bacteria genera between cancer and cancer-adjacent 516 tissues.

518 Both multivariate and univariate discriminant analyses was able to differentiate different 519 tissue sample types based on microbial abundance. As previously reported, cancer and 520 cancer-adjacent tissues were more similar in microbial diversity when compared to noncancer tissues.^{36-38, 42, 43, 45, 49, 51, 52, 55, 57-59, 85} At the genus level, both paired and unpaired 521 522 abundance analysis of cancer and cancer-adjacent tissues showed consistent enrichment for Fusobacterium and Rothia in cancer tissues.^{36, 37, 45, 52, 55, 58, 59} In contrast, Prevotella was 523 524 enriched within cancer tissues compared to cancer-adjacent tissues, and no differences were observed for *Streptococcus*.^{36-38, 41, 43, 45, 51, 52, 55, 57-59, 85} 525

526

527 Previous studies have reported conflicting result where *Fusobacterium* was more in cancer tissues as compared to non-cancer and cancer-adjacent tissues.^{38, 42, 52, 57, 58} However, we 528 529 found that Fusobacterium was most abundant in non-cancer tissues. Fusobacterium is an 530 abundant commensal bacteria found largely in the oral cavity (buccal, hard palate, gingiva, 531 tonsils, tongue) and saliva of healthy individuals, suggesting a potential role within the healthy oral microbiota.¹⁰⁶⁻¹⁰⁸ In vitro experiments in HNSC cell lines showed that 532 533 *Fusobacterium nucleatum* infection promotes cancer cell invasion, proliferation, autophagy, and PD-L1 expression.¹⁰⁹⁻¹¹³ It is unknown whether there are strain and species level 534 535 differences found in Fusobacterium isolated in cancer and non-cancer tissues to explain such 536 seemingly contradictory findings. Additionally, non-cancer tissue from cancer patients may 537 also have different tissue microbiota profiles from healthy donor tissues which is currently 538 unavailable for this study. Also, most of the experiments showing an oncogenic role for F. 539 nucleatum were carried out in vitro and thus did not consider a potential mitigating role of the 540 immune system. Moreover, the abundance of F. nucleatum both in absolute terms and 541 relative to other bacteria present in the tumour microbiota might influence the oncogenic 542 potential of F. nucleatum. Further experiments are required to evaluate the role of 543 Fusobacterium in HNSC.

544

We observed that *Streptococcus*, another highly abundant oral commensal genera¹⁰⁶⁻¹⁰⁸, was increased specifically in cancer and cancer-adjacent tissue when compared to non-cancer tissues. However, there was no significant difference in *Streptococcus* abundance between cancer and cancer-adjacent tissues. Within the oral cavity, certain pathogenic *Streptococcus* species, like *S. mutans*, can contribute to periodontitis by acidifying the environment.¹¹⁴ In oral cancer, *S. mutans* has been shown to promote tumour proliferation and invasion,

potentially through upregulation of IL-6 in infected cells¹¹⁵. On the other hand, *Streptococcus* 551 552 species from the mitis (S. oralis, S parasanguinis, S.mitis) and sanguinis (S. sanguinis, S. 553 gordonii) groups, can break down lactic acid or pyruvate into hydrogen peroxide, thereby antagonising pathogenic species such as S. mutans.¹¹⁴ In oral cancer, S. mitis, S. salivarius, S. 554 555 anginosus were found to display anti-tumour effects, including reducing cancer cell viability and promoting $CD8^+$ cytotoxic T cell responses¹¹⁶⁻¹²⁰. These findings indicate that the 556 557 abundance of specific Streptococcus species may contribute to pathogenesis, disease severity, 558 or exert anti-tumour effects. It is important to note that these studies underscore the 559 limitations of identifying microbiota at the genus level using short-read 16S rRNA 560 sequencing. To address these limitations, recent advances in sequencing technologies such as 561 long-read 16S rRNA amplicon sequencing (e.g., PacBio, Nanopore) or shotgun 562 metagenomics can be employed to reveal species- or strain-specific diversity within the microbiota.¹²¹⁻¹²³ Such advancements can provide a more comprehensive understanding of 563 564 the specific species and strains that play a role in oral cancer pathogenesis and anti-tumour 565 effects.

566

567 To compare the metabolic potential of different head and neck tissue types, a functional 568 prediction analysis was performed using PICRUSt2 on the 16S rRNA sequencing data. The 569 analysis revealed an enrichment of several amino acids and metabolites, including L-570 aspartate, L-asparagine, acetate, butanoate, and lactate, in cancer tissues compared to non-571 cancer and cancer-adjacent tissues. L-aspartate and L-asparagine, as substrates for nucleotide 572 biosynthesis and regulators of amino acid homeostasis and anabolic metabolism, have been reported to promote tumour proliferation.¹²⁴⁻¹²⁶ Butanoate, acetate, and lactate can serve as 573 574 energy sources for cells by converting into acetyl-CoA, which can then be utilized in the tricarboxylic acid (TCA) cycle to produce ATP.¹²⁷⁻¹³⁰ The role of butanoate in tumorigenesis 575

576 depends on the specific tumour and the TME, as it can exhibit tumour-promoting or suppressive properties.^{31, 131-133} Lactate, a well-studied metabolite produced by both cancer 577 578 cells and bacteria, can modulate the TME by inactivating natural killer cells, promoting 579 polarisation of M2-like tumour-associated macrophages, and stimulating the growth of Tregulatory cells.¹³⁴ Collectively, these findings suggest that bacteria infiltrating HNSC tissues 580 581 possess functional capacities that may promote cancer progression. Further validation studies 582 are warranted to better understand the role of these metabolic pathways in HNSC and the 583 contribution of bacteria in shaping the TME.

584

585 We further explored the relationship between the abundance of the five cancer-associated 586 bacterial genera, Fusobacterium, Selenomonas, Treponema, Actinomyces, and Rothia, and the 587 TME phenotype and clinical outcomes. Fusobacterium was associated with a lack of T-cell immune infiltration in HNSC, similar to colorectal and oesophageal cancers.^{21, 135-137} 588 589 Furthermore, Fusobacterium can chemoattract neutrophils via release of SCFA and can also modulate neutrophils and endothelial cell functions in vitro.¹³⁸⁻¹⁴² Interestingly, we observed 590 591 that patients with low levels of *Fusobacterium* within the tumour tissue had shorter overall survival, consistent to previous reports in HNSC.^{45, 60, 143} In contrast, opposite findings have 592 been reported for colorectal, gastric and oesophageal cancers, suggesting that Fusobacterium 593 may have a different role in HNSC.¹⁴⁴⁻¹⁴⁷ We also found that *Treponema* correlated with an 594 595 lack of immune infiltration in HNSC. Although the effect of *Treponema* infiltration in HNSC 596 is still unknown, these bacteria have been associated with an upregulation of immune suppressive cells and can suppress innate immune responses.¹⁴⁸⁻¹⁵⁰ In our analysis, *Rothia* 597 598 was found to correlate with an immune-enriched TME. Limited information is available 599 regarding the role of Rothia in cancer; however, Rothia dentocariosa has been shown to 600 induce Toll-like receptor 2 (TLR-2) mediated TNF-alpha inflammatory response in human

601 embryonic kidney cells and THP-1 monocytes.¹⁵¹ *Selenomonas* and *Actinomyces* did not 602 significantly correlate with TME subtypes in our analysis. However, *Selenomonas sputigena* 603 infected gingival epithelial cells can promote neutrophil and monocyte recruitment.¹⁵² 604 *Actinomyces* has been associated with young-onset colorectal cancers, showing a preferential 605 localisation with cancer-associated fibroblasts in the TME.¹⁵³ These findings underscore the 606 importance of validating and understanding the underlying mechanisms through which these 607 bacteria can modulate the tumour microenvironment in HNSC.

608

609 This study represents the first comprehensive comparison of 16S rRNA (V3-V5) microbial 610 sequencing across multiple studies to identify consensus HNSC-associated microbiota 611 signatures in cancer, cancer-adjacent and non-cancer tissues. To ensure consistency, a 612 uniform bioinformatics approach was employed. However, it is important to acknowledge the 613 inherent limitations of this study. Variations in sample collection, preparation, and 614 sequencing among different laboratories introduce batch effects that could contribute to the 615 inconsistencies observed across different reports. To mitigate these effects, we applied PLSDA-batch adjustment to the pooled datasets.⁹¹ Conventional short-read 16S rRNA 616 617 sequencing provides information only up to the genus level, which restricts the ability to 618 identify specific bacterial species or strains that may be relevant to disease outcomes.¹²¹ 619 Overcoming this limitation would require advanced sequencing technologies such as long-620 read 16S rRNA amplicon sequencing or shotgun metagenomics to reveal species- or strain-621 level diversity within the microbiota. Furthermore, the availability of complete clinical 622 metadata in published datasets reporting 16S rRNA sequencing is limited, restricting our 623 ability to make comprehensive clinical associations. Therefore, our clinical associations were 624 primarily based on TCMA/TCGA datasets. Despite these limitations, this study confirms 625 distinct differences in the microbiota composition among cancer, cancer-adjacent and non-

626 cancer HNSC tissue samples. The strength of our study lies in the meta-analysis of a 627 substantial number of samples, totalling 903. Additionally, our analysis indicates that a high 628 load of *Fusobacterium* within HNSC tissues may be associated with a favourable survival 629 outcome. The correlation analysis of the microbiota with functional predictions, functional 630 gene enrichment signature, and immune subtyping of the tumour and TME provides novel 631 avenues for further exploration.

632

633 In conclusion, our study establishes a consensus microbial signature for head and neck 634 tissues, shedding light on the distinct microbial profiles present in head and neck cancer 635 (HNSC). These findings have the potential to serve as targets for future treatment approaches 636 in HNSC. Nevertheless, it is crucial to acknowledge the limitations identified in our study 637 and recognize the need for further research to address these limitations. Additional 638 investigations are required to gain a deeper understanding of the functional implications of 639 the identified microbiota differences in HNSC. By addressing these gaps, we can advance our 640 knowledge and pave the way for more effective therapeutic interventions in HNSC.

641

642 **5. Conflict of Interest**

643 Authors state no conflict of interest.

644

645 **6. Author Contributions**

646 Conceptualisation K.Y.,K.F.; methodology, investigation, and data analysis, K.Y.,R.L.,F.W.,

647 E.S., G.B., and L.M.; resources A.P., P.W. and S.V.; writing - original draft preparation, K.Y.,

648 E.S., S.V., and K.F; writing-review and editing, K.Y., G.B., E.S., A.P., P.W., R.V., S.V., and

649 K.F.; supervision R.V., A.P., S.V., and K.F.; funding acquisition, A.P., P.W., and S.V.; All

authors have read and agreed to the published version of the manuscript.

651 **7. Acknowledgments**

- 652 This work is supported by an NHMRC investigator grant APP1196832 to P.W., a The
- 653 Garnett Passe and Rodney Williams Senior Fellowship to S.V., and The University of
- 654 Adelaide Postgraduate Research Scholarship to K.Y., R.L., F.W and L.M. Illustration in
- 655 Figure 6 was generated using Biorender.
- 656

657 8. Data Availability Statement

- 658 The data used to support the findings of this study are included within the article and within
- 659 supplementary material.

660 **Reference:**

661 1. Dohlman AB, Arguijo Mendoza D, Ding S, et al. The cancer microbiome atlas: a pan-662 cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. Cell 663 Host Microbe. Feb 10 2021;29(2):281-298.e5. doi:10.1016/j.chom.2020.12.001 664 2. Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of 665 tumor type-specific intracellular bacteria. Science. May 29 2020;368(6494):973-980. 666 doi:10.1126/science.aay9189 667 Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is associated with human 3. 668 breast cancer. PLoS One. 2014;9(1):e83744. doi:10.1371/journal.pone.0083744 669 Jain T, Sharma P, Are AC, Vickers SM, Dudeja V. New Insights Into the Cancer-4. 670 Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front Immunol. 671 2021;12:622064. doi:10.3389/fimmu.2021.622064 Xavier JB, Young VB, Skufca J, et al. The Cancer Microbiome: Distinguishing Direct 672 5. 673 and Indirect Effects Requires a Systemic View. Trends Cancer. Mar 2020;6(3):192-204. 674 doi:10.1016/j.trecan.2020.01.004 675 6. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, 676 development and therapeutic efficacy. Signal Transduct Target Ther. Jan 16 2023;8(1):35. 677 doi:10.1038/s41392-022-01304-4 678 7. Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 679 blockade relies on the gut microbiota. Science. Nov 27 2015;350(6264):1079-84. 680 doi:10.1126/science.aad1329 681 Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes 8. 682 antitumor immunity and facilitates anti-PD-L1 efficacy. Science. Nov 27 683 2015;350(6264):1084-9. doi:10.1126/science.aac4255 684 Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to 9. 685 therapy by modulating the tumor microenvironment. Science. Nov 22 2013;342(6161):967-686 70. doi:10.1126/science.1240527 687 10. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the 688 anticancer immune effects of cyclophosphamide. Science. Nov 22 2013;342(6161):971-6. 689 doi:10.1126/science.1240537 690 11. Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes 691 metastatic colonization in breast cancer. Cell. Apr 14 2022;185(8):1356-1372.e26. 692 doi:10.1016/j.cell.2022.02.027 693 12. Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in 694 mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. Sep 15 695 2017;357(6356):1156-1160. doi:10.1126/science.aah5043 696 13. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum Promotes Chemoresistance to 697 Colorectal Cancer by Modulating Autophagy. Cell. Jul 27 2017;170(3):548-563.e16. 698 doi:10.1016/j.cell.2017.07.008 699 14. Spanogiannopoulos P, Kyaw TS, Guthrie BGH, et al. Host and gut bacteria share 700 metabolic pathways for anti-cancer drug metabolism. Nat Microbiol. Oct 2022;7(10):1605-701 1620. doi:10.1038/s41564-022-01226-5 702 15. Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium 703 nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. 704 Immunity. Feb 17 2015;42(2):344-355. doi:10.1016/j.immuni.2015.01.010 705 16. Kalaora S, Nagler A, Nejman D, et al. Identification of bacteria-derived HLA-bound 706 peptides in melanoma. Nature. Apr 2021;592(7852):138-143. doi:10.1038/s41586-021-707 03368-8

708 17. Naghavian R, Faigle W, Oldrati P, et al. Microbial peptides activate tumour-709 infiltrating lymphocytes in glioblastoma. Nature. May 2023;617(7962):807-817. 710 doi:10.1038/s41586-023-06081-w 711 18. Abed J, Emgård JE, Zamir G, et al. Fap2 Mediates Fusobacterium nucleatum 712 Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc. Cell 713 Host Microbe. Aug 10 2016;20(2):215-25. doi:10.1016/j.chom.2016.07.006 714 19. Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by Fusobacterium 715 nucleatum accelerates tumor growth and metastatic progression. Nat Commun. Jun 26 716 2020;11(1):3259. doi:10.1038/s41467-020-16967-2 717 20. Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes 718 chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. 719 J Exp Clin Cancer Res. Jan 10 2019;38(1):14. doi:10.1186/s13046-018-0985-y 720 21. Wu J, Li Q, Fu X. Fusobacterium nucleatum Contributes to the Carcinogenesis of 721 Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity. Transl Oncol. 722 Jun 2019;12(6):846-851. doi:10.1016/j.tranon.2019.03.003 723 22. Gur C, Maalouf N, Shhadeh A, et al. Fusobacterium nucleatum supresses anti-tumor 724 immunity by activating CEACAM1. Oncoimmunology. 2019;8(6):e1581531. 725 doi:10.1080/2162402x.2019.1581531 726 23. Yoon Y, Kim G, Jeon BN, Fang S, Park H. Bifidobacterium Strain-Specific Enhances 727 the Efficacy of Cancer Therapeutics in Tumor-Bearing Mice. Cancers (Basel). Feb 25 728 2021;13(5)doi:10.3390/cancers13050957 729 24. Asadollahi P, Ghanavati R, Rohani M, Razavi S, Esghaei M, Talebi M. Anti-cancer 730 effects of Bifidobacterium species in colon cancer cells and a mouse model of carcinogenesis. 731 PLoS One. 2020;15(5):e0232930. doi:10.1371/journal.pone.0232930 732 25. Rossi T, Vergara D, Fanini F, Maffia M, Bravaccini S, Pirini F. Microbiota-Derived 733 Metabolites in Tumor Progression and Metastasis. Int J Mol Sci. Aug 12 734 2020;21(16)doi:10.3390/ijms21165786 735 26. Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom 736 intermediates. Nat Rev Microbiol. Feb 2021;19(2):77-94. doi:10.1038/s41579-020-0438-4 737 Bachem A, Makhlouf C, Binger KJ, et al. Microbiota-Derived Short-Chain Fatty 27. 738 Acids Promote the Memory Potential of Antigen-Activated CD8(+) T Cells. Immunity. Aug 739 20 2019;51(2):285-297.e5. doi:10.1016/j.immuni.2019.06.002 740 28. Wang W, Fang D, Zhang H, et al. Sodium Butyrate Selectively Kills Cancer Cells and 741 Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1. Onco Targets Ther. 742 2020;13:4691-4704. doi:10.2147/ott.S235575 743 29. Liang Y, Rao Z, Du D, Wang Y, Fang T. Butyrate prevents the migration and 744 invasion, and aerobic glycolysis in gastric cancer via inhibiting Wnt/ β -catenin/c-Myc 745 signaling. Drug Dev Res. May 2023;84(3):532-541. doi:10.1002/ddr.22043 746 30. He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy 747 efficacy by modulating cytotoxic CD8(+) T cell immunity. *Cell Metab.* May 4 748 2021;33(5):988-1000.e7. doi:10.1016/j.cmet.2021.03.002 749 31. Okumura S, Konishi Y, Narukawa M, et al. Gut bacteria identified in colorectal 750 cancer patients promote tumourigenesis via butyrate secretion. Nat Commun. Sep 28 751 2021;12(1):5674. doi:10.1038/s41467-021-25965-x 752 32. Zaiatz-Bittencourt V, Jones F, Tosetto M, et al. Butyrate limits human natural killer 753 cell effector function. Sci Rep. Feb 15 2023;13(1):2715. doi:10.1038/s41598-023-29731-5 754 33. Bender MJ, McPherson AC, Phelps CM, et al. Dietary tryptophan metabolite released 755 by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 756 Apr 27 2023;186(9):1846-1862.e26. doi:10.1016/j.cell.2023.03.011

34. 757 Tintelnot J, Xu Y, Lesker TR, et al. Microbiota-derived 3-IAA influences 758 chemotherapy efficacy in pancreatic cancer. Nature. Mar 2023;615(7950):168-174. 759 doi:10.1038/s41586-023-05728-y 760 35. Hezaveh K, Shinde RS, Klötgen A, et al. Tryptophan-derived microbial metabolites 761 activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-762 tumor immunity. Immunity. Feb 8 2022;55(2):324-340.e8. doi:10.1016/j.immuni.2022.01.006 763 36. Chang C, Geng F, Shi X, et al. The prevalence rate of periodontal pathogens and its 764 association with oral squamous cell carcinoma. Appl Microbiol Biotechnol. Feb 765 2019;103(3):1393-1404. doi:10.1007/s00253-018-9475-6 766 37. Zhou J, Wang L, Yuan R, et al. Signatures of Mucosal Microbiome in Oral Squamous 767 Cell Carcinoma Identified Using a Random Forest Model. Cancer Manag Res. 768 2020;12:5353-5363. doi:10.2147/cmar.S251021 769 38. Torralba MG, Aleti G, Li W, et al. Oral Microbial Species and Virulence Factors 770 Associated with Oral Squamous Cell Carcinoma. Microb Ecol. Nov 2021;82(4):1030-1046. 771 doi:10.1007/s00248-020-01596-5 772 39. Henrich B, Rumming M, Sczyrba A, et al. Mycoplasma salivarium as a dominant 773 coloniser of Fanconi anaemia associated oral carcinoma. PLoS One. 2014;9(3):e92297. 774 doi:10.1371/journal.pone.0092297 775 Chan JYK, Ng CWK, Lan L, et al. Restoration of the Oral Microbiota After Surgery 40. 776 for Head and Neck Squamous Cell Carcinoma Is Associated With Patient Outcomes. Front 777 Oncol. 2021;11:737843. doi:10.3389/fonc.2021.737843 778 41. De Martin A, Lütge M, Stanossek Y, et al. Distinct microbial communities colonize 779 tonsillar squamous cell carcinoma. Oncoimmunology. 2021;10(1):1945202. 780 doi:10.1080/2162402x.2021.1945202 781 42. Zakrzewski M, Gannon OM, Panizza BJ, Saunders NA, Antonsson A. Human 782 papillomavirus infection and tumor microenvironment are associated with the microbiota in 783 patients with oropharyngeal cancers-pilot study. Head Neck. Nov 2021;43(11):3324-3330. 784 doi:10.1002/hed.26821 785 43. Sarkar P, Malik S, Laha S, et al. Dysbiosis of Oral Microbiota During Oral Squamous 786 Cell Carcinoma Development. Front Oncol. 2021;11:614448. doi:10.3389/fonc.2021.614448 787 44. Zhou X, Hao Y, Peng X, et al. The Clinical Potential of Oral Microbiota as a 788 Screening Tool for Oral Squamous Cell Carcinomas. Front Cell Infect Microbiol. 789 2021;11:728933. doi:10.3389/fcimb.2021.728933 790 Chen Z, Wong PY, Ng CWK, et al. The Intersection between Oral Microbiota, Host 45. 791 Gene Methylation and Patient Outcomes in Head and Neck Squamous Cell Carcinoma. 792 *Cancers (Basel).* Nov 18 2020;12(11)doi:10.3390/cancers12113425 793 Perera M, Al-Hebshi NN, Perera I, et al. Inflammatory Bacteriome and Oral 46. 794 Squamous Cell Carcinoma. J Dent Res. Jun 2018;97(6):725-732. 795 doi:10.1177/0022034518767118 796 47. Al-Hebshi NN, Nasher AT, Maryoud MY, et al. Inflammatory bacteriome featuring 797 Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral 798 squamous cell carcinoma. Sci Rep. May 12 2017;7(1):1834. doi:10.1038/s41598-017-02079-799 3 800 48. Schmidt BL, Kuczynski J, Bhattacharya A, et al. Changes in abundance of oral 801 microbiota associated with oral cancer. PLoS One. 2014;9(6):e98741. 802 doi:10.1371/journal.pone.0098741 803 49. Wang H, Funchain P, Bebek G, et al. Microbiomic differences in tumor and paired-804 normal tissue in head and neck squamous cell carcinomas. Genome Med. Feb 7 2017;9(1):14.

805 doi:10.1186/s13073-017-0405-5

806 50. Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, et al. 16S rRNA amplicon 807 sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget. Aug 9 2016;7(32):51320-51334. 808 809 doi:10.18632/oncotarget.9710 810 51. Gong H, Shi Y, Zhou X, et al. Microbiota in the Throat and Risk Factors for 811 Laryngeal Carcinoma. Appl Environ Microbiol. Dec 2014;80(23):7356-63. 812 doi:10.1128/aem.02329-14 813 52. Gong HL, Shi Y, Zhou L, et al. The Composition of Microbiome in Larynx and the 814 Throat Biodiversity between Laryngeal Squamous Cell Carcinoma Patients and Control 815 Population. PLoS One. 2013;8(6):e66476. doi:10.1371/journal.pone.0066476 816 53. Pushalkar S, Ji X, Li Y, et al. Comparison of oral microbiota in tumor and non-tumor 817 tissues of patients with oral squamous cell carcinoma. BMC Microbiol. Jul 20 2012;12:144. 818 doi:10.1186/1471-2180-12-144 Burcher KM, Burcher JT, Inscore L, Bloomer CH, Furdui CM, Porosnicu M. A 819 54. 820 Review of the Role of Oral Microbiome in the Development, Detection, and Management of 821 Head and Neck Squamous Cell Cancers. Cancers (Basel). Aug 25 822 2022;14(17)doi:10.3390/cancers14174116 823 55. Yang K, Wang Y, Zhang S, et al. Oral Microbiota Analysis of Tissue Pairs and Saliva 824 Samples From Patients With Oral Squamous Cell Carcinoma - A Pilot Study. Front 825 Microbiol. 2021;12:719601. doi:10.3389/fmicb.2021.719601 826 56. Gopinath D, Kunnath Menon R, Chun Wie C, et al. Salivary bacterial shifts in oral 827 leukoplakia resemble the dysbiotic oral cancer bacteriome. J Oral Microbiol. Dec 9 828 2020;13(1):1857998. doi:10.1080/20002297.2020.1857998 829 Gong H, Shi Y, Xiao X, et al. Alterations of microbiota structure in the larynx 57. 830 relevant to laryngeal carcinoma. Sci Rep. Jul 14 2017;7(1):5507. doi:10.1038/s41598-017-831 05576-7 832 58. Dong Z, Zhang C, Zhao Q, et al. Alterations of bacterial communities of vocal cord 833 mucous membrane increases the risk for glottic larvngeal squamous cell carcinoma. J 834 *Cancer*. 2021;12(13):4049-4063. doi:10.7150/jca.54221 835 59. Shin JM, Luo T, Kamarajan P, Fenno JC, Rickard AH, Kapila YL. Microbial 836 Communities Associated with Primary and Metastatic Head and Neck Squamous Cell 837 Carcinoma - A High Fusobacterial and Low Streptococcal Signature. Sci Rep. Aug 30 838 2017;7(1):9934. doi:10.1038/s41598-017-09786-x 839 Chan JYK, Cheung MK, Lan L, et al. Characterization of oral microbiota in HPV and 60. 840 non-HPV head and neck squamous cell carcinoma and its association with patient outcomes. 841 Oral Oncol. Dec 2022;135:106245. doi:10.1016/j.oraloncology.2022.106245 842 61. Choi YS, Kim Y, Yoon HJ, et al. The presence of bacteria within tissue provides 843 insights into the pathogenesis of oral lichen planus. Sci Rep. Jul 7 2016;6:29186. 844 doi:10.1038/srep29186 845 Baek K, Lee J, Lee A, et al. Characterization of intratissue bacterial communities and 62. 846 isolation of Escherichia coli from oral lichen planus lesions. Sci Rep. Feb 26 847 2020;10(1):3495. doi:10.1038/s41598-020-60449-w 848 63. Bao K, Li X, Poveda L, et al. Proteome and Microbiome Mapping of Human Gingival 849 Tissue in Health and Disease. Front Cell Infect Microbiol. 2020;10:588155. 850 doi:10.3389/fcimb.2020.588155 851 64. Sawant S, Dugad J, Parikh D, Srinivasan S, Singh H. Identification & correlation of 852 bacterial diversity in oral cancer and long-term tobacco chewers- A case-control pilot study. J 853 Med Microbiol. Sep 2021;70(9)doi:10.1099/jmm.0.001417

854 65. Frank DN, Qiu Y, Cao Y, et al. A dysbiotic microbiome promotes head and neck 855 squamous cell carcinoma. Oncogene. Feb 2022;41(9):1269-1280. doi:10.1038/s41388-021-856 02137-1 857 66. Sharma AK, DeBusk WT, Stepanov I, Gomez A, Khariwala SS. Oral Microbiome 858 Profiling in Smokers with and without Head and Neck Cancer Reveals Variations Between 859 Health and Disease. Cancer Prev Res (Phila). May 2020;13(5):463-474. doi:10.1158/1940-860 6207.Capr-19-0459 861 67. Lau HC, Hsueh CY, Gong H, et al. Oropharynx microbiota transitions in 862 hypopharyngeal carcinoma treatment of induced chemotherapy followed by surgery. BMC 863 Microbiol. Nov 9 2021;21(1):310. doi:10.1186/s12866-021-02362-4 864 68. Hsueh CY, Gong H, Cong N, et al. Throat Microbial Community Structure and 865 Functional Changes in Postsurgery Laryngeal Carcinoma Patients. Appl Environ Microbiol. 866 Nov 24 2020;86(24)doi:10.1128/aem.01849-20 867 69. Panda M, Rai AK, Rahman T, et al. Alterations of salivary microbial community 868 associated with oropharyngeal and hypopharyngeal squamous cell carcinoma patients. Arch 869 Microbiol. May 2020;202(4):785-805. doi:10.1007/s00203-019-01790-1 870 70. Vesty A, Gear K, Biswas K, Radcliff FJ, Taylor MW, Douglas RG. Microbial and 871 inflammatory-based salivary biomarkers of head and neck squamous cell carcinoma. Clin 872 Exp Dent Res. Dec 2018;4(6):255-262. doi:10.1002/cre2.139 873 71. Lee WH, Chen HM, Yang SF, et al. Bacterial alterations in salivary microbiota and 874 their association in oral cancer. Sci Rep. Nov 28 2017;7(1):16540. doi:10.1038/s41598-017-16418-x 875 876 72. Amer A, Galvin S, Healy CM, Moran GP. The Microbiome of Potentially Malignant 877 Oral Leukoplakia Exhibits Enrichment for Fusobacterium, Leptotrichia, Campylobacter, and 878 Rothia Species. Front Microbiol. 2017;8:2391. doi:10.3389/fmicb.2017.02391 879 Chen MY, Chen JW, Wu LW, et al. Carcinogenesis of Male Oral Submucous Fibrosis 73. 880 Alters Salivary Microbiomes. J Dent Res. Apr 2021;100(4):397-405. 881 doi:10.1177/0022034520968750 882 74. Debelius JW, Huang T, Cai Y, et al. Subspecies Niche Specialization in the Oral 883 Microbiome Is Associated with Nasopharyngeal Carcinoma Risk. mSystems. Jul 7 884 2020;5(4)doi:10.1128/mSystems.00065-20 885 75. Kumpitsch C, Moissl-Eichinger C, Pock J, Thurnher D, Wolf A. Preliminary insights 886 into the impact of primary radiochemotherapy on the salivary microbiome in head and neck 887 squamous cell carcinoma. Sci Rep. Oct 6 2020;10(1):16582. doi:10.1038/s41598-020-73515-888 0 889 76. Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV, Thurnher D. The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal 890 891 squamous cell carcinoma: A pilot study. Sci Rep. Jul 19 2017;7(1):5867. doi:10.1038/s41598-892 017-06361-2 893 77. Zhu XX, Yang XJ, Chao YL, et al. The Potential Effect of Oral Microbiota in the 894 Prediction of Mucositis During Radiotherapy for Nasopharyngeal Carcinoma. EBioMedicine. 895 Apr 2017;18:23-31. doi:10.1016/j.ebiom.2017.02.002 896 78. Furguim CP, Soares GM, Ribeiro LL, et al. The Salivary Microbiome and Oral 897 Cancer Risk: a Pilot Study in Fanconi Anemia. J Dent Res. Mar 2017;96(3):292-299. 898 doi:10.1177/0022034516678169 899 79. Zhang J, Liu H, Liang X, et al. Investigation of salivary function and oral microbiota 900 of radiation caries-free people with nasopharyngeal carcinoma. PLoS One.

901 2015;10(4):e0123137. doi:10.1371/journal.pone.0123137

80. 902 Hu YJ, Wang Q, Jiang YT, et al. Characterization of oral bacterial diversity of 903 irradiated patients by high-throughput sequencing. Int J Oral Sci. Mar 2013;5(1):21-5. 904 doi:10.1038/ijos.2013.15 905 81. Pushalkar S, Mane SP, Ji X, et al. Microbial diversity in saliva of oral squamous cell 906 carcinoma. FEMS Immunol Med Microbiol. Apr 2011;61(3):269-77. doi:10.1111/j.1574-907 695X.2010.00773.x 908 82. Hu YJ, Shao ZY, Wang Q, et al. Exploring the dynamic core microbiome of plaque 909 microbiota during head-and-neck radiotherapy using pyrosequencing. PLoS One. 910 2013;8(2):e56343. doi:10.1371/journal.pone.0056343 911 83. Minarovits J. Anaerobic bacterial communities associated with oral carcinoma: 912 Intratumoral, surface-biofilm and salivary microbiota. Anaerobe. Apr 2021;68:102300. 913 doi:10.1016/j.anaerobe.2020.102300 914 84. Orlandi E, Iacovelli NA, Tombolini V, et al. Potential role of microbiome in 915 oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer. Oral 916 Oncol. Dec 2019;99:104453. doi:10.1016/j.oraloncology.2019.104453 917 85. Gopinath D, Menon RK, Wie CC, et al. Differences in the bacteriome of swab, saliva, 918 and tissue biopsies in oral cancer. Sci Rep. Jan 13 2021;11(1):1181. doi:10.1038/s41598-020-919 80859-0 920 86. Jain V, Baraniya D, El-Hadedy DE, et al. Integrative Metatranscriptomic Analysis 921 Reveals Disease-specific Microbiome-host Interactions in Oral Squamous Cell Carcinoma. 922 Cancer Res Commun. 2023;3(5):807-820. doi:10.1158/2767-9764.CRC-22-0349 923 87. Wang X, Zhao Z, Tang N, et al. Microbial Community Analysis of Saliva and 924 Biopsies in Patients With Oral Lichen Planus. Front Microbiol. 2020;11:629. 925 doi:10.3389/fmicb.2020.00629 926 88. Zhang Z, Feng Q, Li M, et al. Age-Related Cancer-Associated Microbiota Potentially 927 Promotes Oral Squamous Cell Cancer Tumorigenesis by Distinct Mechanisms. Front 928 Microbiol. 2022;13:852566. doi:10.3389/fmicb.2022.852566 929 89. Nie F, Wang L, Huang Y, et al. Characteristics of Microbial Distribution in Different 930 Oral Niches of Oral Squamous Cell Carcinoma. Front Cell Infect Microbiol. 931 2022;12:905653. doi:10.3389/fcimb.2022.905653 932 90. Qiao H, Li H, Wen X, Tan X, Yang C, Liu N. Multi-Omics Integration Reveals the 933 Crucial Role of Fusobacterium in the Inflammatory Immune Microenvironment in Head and 934 Neck Squamous Cell Carcinoma. *Microbiol Spectr.* Aug 31 2022;10(4):e0106822. 935 doi:10.1128/spectrum.01068-22 936 91. Wang Y, KA LC. PLSDA-batch: a multivariate framework to correct for batch effects 937 in microbiome data. Brief Bioinform. Mar 19 2023;24(2)doi:10.1093/bib/bbac622 938 92. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated 939 guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). Sep 2021;74(9):790-940 799. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones 941 sistemáticas. doi:10.1016/j.rec.2021.07.010 942 93. Choudhary S. pysradb: A Python package to query next-generation sequencing 943 metadata and data from NCBI Sequence Read Archive. F1000Res. 2019;8:532. 944 doi:10.12688/f1000research.18676.1 945 94. Leinonen R, Sugawara H, Shumway M. The sequence read archive. Nucleic Acids 946 Res. Jan 2011;39(Database issue):D19-21. doi:10.1093/nar/gkq1019 947 95. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and 948 extensible microbiome data science using QIIME 2. Nat Biotechnol. Aug 2019;37(8):852-949 857. doi:10.1038/s41587-019-0209-9

96. 950 Rohart F, Gautier B, Singh A, KA LC. mixOmics: An R package for 'omics feature 951 selection and multiple data integration. PLoS Comput Biol. Nov 2017;13(11):e1005752. 952 doi:10.1371/journal.pcbi.1005752 953 97. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis 954 and graphics of microbiome census data. PLoS One. 2013;8(4):e61217. 955 doi:10.1371/journal.pone.0061217 Moentadj R, Wang Y, Bowerman K, et al. Streptococcus species enriched in the oral 956 98. 957 cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can 958 induce arthritis in mice. Ann Rheum Dis. May 2021;80(5):573-581. 959 doi:10.1136/annrheumdis-2020-219009 960 99. Gloor GB, Macklaim JM, Pawlowsky-Glahn V, Egozcue JJ. Microbiome Datasets 961 Are Compositional: And This Is Not Optional. Front Microbiol. 2017;8:2224. 962 doi:10.3389/fmicb.2017.02224 963 100. Khomich M, Måge I, Rud I, Berget I. Analysing microbiome intervention design 964 studies: Comparison of alternative multivariate statistical methods. PLoS One. 965 2021;16(11):e0259973. doi:10.1371/journal.pone.0259973 966 101. Cao Y, Dong O, Wang D, Zhang P, Liu Y, Niu C. microbiomeMarker: an 967 R/Bioconductor package for microbiome marker identification and visualization. 968 Bioinformatics. Aug 10 2022;38(16):4027-4029. doi:10.1093/bioinformatics/btac438 969 Douglas GM, Maffei VJ, Zaneveld JR, et al. PICRUSt2 for prediction of metagenome 102. 970 functions. Nat Biotechnol. Jun 2020;38(6):685-688. doi:10.1038/s41587-020-0548-6 971 103. Caspi R, Billington R, Keseler IM, et al. The MetaCyc database of metabolic 972 pathways and enzymes - a 2019 update. Nucleic Acids Res. Jan 8 2020;48(D1):D445-d453. 973 doi:10.1093/nar/gkz862 974 104. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer 975 genomics and clinical profiles using the cBioPortal. Sci Signal. Apr 2 2013;6(269):pl1. 976 doi:10.1126/scisignal.2004088 977 Bagaev A, Kotlov N, Nomie K, et al. Conserved pan-cancer microenvironment 105. 978 subtypes predict response to immunotherapy. Cancer Cell. Jun 14 2021;39(6):845-865.e7. 979 doi:10.1016/j.ccell.2021.04.014 980 Eren AM, Borisy GG, Huse SM, Mark Welch JL. Oligotyping analysis of the human 106. 981 oral microbiome. Proc Natl Acad Sci U S A. Jul 15 2014;111(28):E2875-84. 982 doi:10.1073/pnas.1409644111 983 Mark Welch JL, Rossetti BJ, Rieken CW, Dewhirst FE, Borisy GG. Biogeography of 107. 984 a human oral microbiome at the micron scale. Proc Natl Acad Sci USA. Feb 9 985 2016;113(6):E791-800. doi:10.1073/pnas.1522149113 986 Wilbert SA, Mark Welch JL, Borisy GG. Spatial Ecology of the Human Tongue 108. 987 Dorsum Microbiome. Cell Rep. Mar 24 2020;30(12):4003-4015.e3. 988 doi:10.1016/j.celrep.2020.02.097 989 109. Shao W, Fujiwara N, Mouri Y, et al. Conversion from epithelial to partial-EMT 990 phenotype by Fusobacterium nucleatum infection promotes invasion of oral cancer cells. Sci 991 *Rep.* Jul 22 2021;11(1):14943. doi:10.1038/s41598-021-94384-1 992 110. Chen G, Gao C, Jiang S, et al. Fusobacterium nucleatum outer membrane vesicles 993 activate autophagy to promote oral cancer metastasis. J Adv Res. Apr 13 994 2023;doi:10.1016/j.jare.2023.04.002 995 111. Geng F, Zhang Y, Lu Z, Zhang S, Pan Y. Fusobacterium nucleatum Caused DNA 996 Damage and Promoted Cell Proliferation by the Ku70/p53 Pathway in Oral Cancer Cells. 997 DNA Cell Biol. Jan 2020;39(1):144-151. doi:10.1089/dna.2019.5064 998 112. Zhang S, Li C, Liu J, et al. Fusobacterium nucleatum promotes epithelial-999 mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-

1000 5p/Akt2/SNAI1 signaling pathway. *Febs j.* Sep 2020;287(18):4032-4047. 1001 doi:10.1111/febs.15233 1002 113. Binder Gallimidi A, Fischman S, Revach B, et al. Periodontal pathogens 1003 Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an 1004 oral-specific chemical carcinogenesis model. Oncotarget. Sep 8 2015;6(26):22613-23. 1005 doi:10.18632/oncotarget.4209 1006 114. Baty JJ, Stoner SN, Scoffield JA. Oral Commensal Streptococci: Gatekeepers of the 1007 Oral Cavity. J Bacteriol. Nov 15 2022;204(11):e0025722. doi:10.1128/jb.00257-22 1008 Tsai MS, Chen YY, Chen WC, Chen MF. Streptococcus mutans promotes tumor 115. 1009 progression in oral squamous cell carcinoma. J Cancer. 2022;13(12):3358-3367. 1010 doi:10.7150/jca.73310 1011 116. Baraniya D, Jain V, Lucarelli R, et al. Screening of Health-Associated Oral Bacteria 1012 for Anticancer Properties in vitro. Front Cell Infect Microbiol. 2020;10:575656. 1013 doi:10.3389/fcimb.2020.575656 1014 Xu Y, Jia Y, Chen L, Gao J, Yang D. Effect of Streptococcus anginosus on biological 117. 1015 response of tongue squamous cell carcinoma cells. BMC Oral Health. Mar 20 1016 2021;21(1):141. doi:10.1186/s12903-021-01505-3 1017 118. Baraniya D, Chitrala KN, Al-Hebshi NN. Global transcriptional response of oral 1018 squamous cell carcinoma cell lines to health-associated oral bacteria - an in vitro study. J 1019 Oral Microbiol. 2022;14(1):2073866. doi:10.1080/20002297.2022.2073866 1020 119. Wang J, Sun F, Lin X, Li Z, Mao X, Jiang C. Cytotoxic T cell responses to 1021 Streptococcus are associated with improved prognosis of oral squamous cell carcinoma. Exp 1022 Cell Res. Jan 1 2018;362(1):203-208. doi:10.1016/j.yexcr.2017.11.018 1023 Wang J, Yang L, Mao X, Li Z, Lin X, Jiang C. Streptococcus salivarius-mediated 120. 1024 CD8(+) T cell stimulation required antigen presentation by macrophages in oral squamous 1025 cell carcinoma. Exp Cell Res. May 15 2018;366(2):121-126. doi:10.1016/j.yexcr.2018.03.007 1026 121. Curry KD, Wang Q, Nute MG, et al. Emu: species-level microbial community 1027 profiling of full-length 16S rRNA Oxford Nanopore sequencing data. *Nat Methods*. Jul 1028 2022;19(7):845-853. doi:10.1038/s41592-022-01520-4 1029 122. Johnson JS, Spakowicz DJ, Hong BY, et al. Evaluation of 16S rRNA gene sequencing 1030 for species and strain-level microbiome analysis. *Nat Commun.* Nov 6 2019;10(1):5029. 1031 doi:10.1038/s41467-019-13036-1 1032 123. Gehrig JL, Portik DM, Driscoll MD, et al. Finding the right fit: evaluation of short-1033 read and long-read sequencing approaches to maximize the utility of clinical microbiome 1034 data. Microb Genom. Mar 2022;8(3)doi:10.1099/mgen.0.000794 1035 124. Garcia-Bermudez J, Baudrier L, La K, et al. Aspartate is a limiting metabolite for 1036 cancer cell proliferation under hypoxia and in tumours. Nat Cell Biol. Jul 2018;20(7):775-1037 781. doi:10.1038/s41556-018-0118-z 1038 Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer 125. 1039 cell proliferation through use as an amino acid exchange factor. Nat Commun. Apr 29 1040 2016;7:11457. doi:10.1038/ncomms11457 1041 Halbrook CJ, Thurston G, Boyer S, et al. Differential integrated stress response and 126. 1042 asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma 1043 cells. Nat Cancer. Nov 2022;3(11):1386-1403. doi:10.1038/s43018-022-00463-1 1044 Donohoe DR, Garge N, Zhang X, et al. The microbiome and butyrate regulate energy 127. 1045 metabolism and autophagy in the mammalian colon. Cell Metab. May 4 2011;13(5):517-26. 1046 doi:10.1016/j.cmet.2011.02.018 1047 Mashimo T, Pichumani K, Vemireddy V, et al. Acetate is a bioenergetic substrate for 128. 1048 human glioblastoma and brain metastases. Cell. Dec 18 2014;159(7):1603-14.

1049 doi:10.1016/j.cell.2014.11.025

1050 129. Lyssiotis CA, Cantley LC. Acetate fuels the cancer engine. Cell. Dec 18 1051 2014;159(7):1492-4. doi:10.1016/j.cell.2014.12.009 1052 130. Comerford SA, Huang Z, Du X, et al. Acetate dependence of tumors. Cell. Dec 18 1053 2014;159(7):1591-602. doi:10.1016/j.cell.2014.11.020 1054 Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect 131. 1055 dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol 1056 Cell. Nov 30 2012;48(4):612-26. doi:10.1016/j.molcel.2012.08.033 1057 Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to 132. 1058 Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. Jun 2 1059 2016;165(6):1332-1345. doi:10.1016/j.cell.2016.05.041 1060 van der Hee B, Wells JM. Microbial Regulation of Host Physiology by Short-chain 133. 1061 Fatty Acids. Trends Microbiol. Aug 2021;29(8):700-712. doi:10.1016/j.tim.2021.02.001 1062 Li Z, Wang Q, Huang X, et al. Lactate in the tumor microenvironment: A rising star 134. 1063 for targeted tumor therapy. Front Nutr. 2023;10:1113739. doi:10.3389/fnut.2023.1113739 1064 135. Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T Cells in 1065 Colorectal Carcinoma. JAMA Oncol. Aug 2015;1(5):653-61. 1066 doi:10.1001/jamaoncol.2015.1377 Kim HS, Kim CG, Kim WK, et al. Fusobacterium nucleatum induces a tumor 1067 136. 1068 microenvironment with diminished adaptive immunity against colorectal cancers. Front Cell 1069 Infect Microbiol. 2023;13:1101291. doi:10.3389/fcimb.2023.1101291 1070 Kosumi K, Baba Y, Yamamura K, et al. Intratumour Fusobacterium nucleatum and 137. 1071 immune response to oesophageal cancer. Br J Cancer. Apr 2023;128(6):1155-1165. 1072 doi:10.1038/s41416-022-02112-x 1073 138. Dahlstrand Rudin A, Khamzeh A, Venkatakrishnan V, Basic A, Christenson K, 1074 Bylund J. Short chain fatty acids released by Fusobacterium nucleatum are neutrophil 1075 chemoattractants acting via free fatty acid receptor 2 (FFAR2). Cell Microbiol. Aug 1076 2021;23(8):e13348. doi:10.1111/cmi.13348 1077 Mendes RT, Nguyen D, Stephens D, et al. Endothelial Cell Response to 139. 1078 Fusobacterium nucleatum. Infect Immun. Jul 2016;84(7):2141-2148. doi:10.1128/iai.01305-1079 15 1080 Wang O, Zhao L, Xu C, Zhou J, Wu Y. Fusobacterium nucleatum stimulates 140. 1081 monocyte adhesion to and transmigration through endothelial cells. Arch Oral Biol. Apr 1082 2019;100:86-92. doi:10.1016/j.archoralbio.2019.02.013 1083 Wright HJ, Chapple IL, Matthews JB, Cooper PR. Fusobacterium nucleatum 141. 1084 regulation of neutrophil transcription. J Periodontal Res. Feb 2011;46(1):1-12. 1085 doi:10.1111/j.1600-0765.2010.01299.x 1086 Zhou T, Meng X, Wang D, Fu W, Li X. Neutrophil Transcriptional Deregulation by 142. 1087 the Periodontal Pathogen Fusobacterium nucleatum in Gastric Cancer: A Bioinformatic 1088 Study. Dis Markers. 2022;2022:9584507. doi:10.1155/2022/9584507 1089 143. Neuzillet C, Marchais M, Vacher S, et al. Prognostic value of intratumoral 1090 Fusobacterium nucleatum and association with immune-related gene expression in oral 1091 squamous cell carcinoma patients. Sci Rep. Apr 12 2021;11(1):7870. doi:10.1038/s41598-1092 021-86816-9 1093 Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal 144. 1094 carcinoma tissue and patient prognosis. Gut. Dec 2016;65(12):1973-1980. 1095 doi:10.1136/gutjnl-2015-310101 1096 145. Lehr K, Nikitina D, Vilchez-Vargas R, et al. Microbial composition of tumorous and 1097 adjacent gastric tissue is associated with prognosis of gastric cancer. Sci Rep. Mar 21 1098 2023;13(1):4640. doi:10.1038/s41598-023-31740-3

- 1099 146. Hsieh YY, Kuo WL, Hsu WT, Tung SY, Li C. Fusobacterium Nucleatum-Induced
- 1100 Tumor Mutation Burden Predicts Poor Survival of Gastric Cancer Patients. Cancers (Basel).
- 1101 Dec 30 2022;15(1)doi:10.3390/cancers15010269
- 1102 147. Zhang N, Liu Y, Yang H, et al. Clinical Significance of Fusobacterium nucleatum
- 1103 Infection and Regulatory T Cell Enrichment in Esophageal Squamous Cell Carcinoma.
- 1104 Pathol Oncol Res. 2021;27:1609846. doi:10.3389/pore.2021.1609846
- 1105 148. Jo AR, Baek KJ, Shin JE, Choi Y. Mechanisms of IL-8 suppression by Treponema
- 1106 denticola in gingival epithelial cells. *Immunol Cell Biol*. Feb 2014;92(2):139-47.
- 1107 doi:10.1038/icb.2013.80
- 1108 149. Babolin C, Amedei A, Ozolins D, Zilevica A, D'Elios MM, de Bernard M. TpF1 from
- 1109 Treponema pallidum activates inflammasome and promotes the development of regulatory T
- 1110 cells. J Immunol. Aug 1 2011;187(3):1377-84. doi:10.4049/jimmunol.1100615
- 1111 150. Hashimoto M, Asai Y, Ogawa T. Treponemal phospholipids inhibit innate immune
- 1112 responses induced by pathogen-associated molecular patterns. J Biol Chem. Nov 7
- 1113 2003;278(45):44205-13. doi:10.1074/jbc.M306735200
- 1114 151. Kataoka H, Taniguchi M, Fukamachi H, Arimoto T, Morisaki H, Kuwata H. Rothia
- dentocariosa induces TNF-alpha production in a TLR2-dependent manner. *Pathog Dis.* Jun
 2014;71(1):65-8. doi:10.1111/2049-632x.12115
- 1117 152. Hawkes CG, Hinson AN, Vashishta A, et al. Selenomonas sputigena Interactions with
- 1118 Gingival Epithelial Cells That Promote Inflammation. Infect Immun. Feb 16
- 1119 2023;91(2):e0031922. doi:10.1128/iai.00319-22
- 1120 153. Xu Z, Lv Z, Chen F, et al. Dysbiosis of human tumor microbiome and aberrant
- 1121 residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer.
- 1122 Front Immunol. 2022;13:1008975. doi:10.3389/fimmu.2022.1008975

- 1124 Supplementary Figures
- 1125
- 1126
- 1127



1128

Figure S1: CLR-normalized abundances for remaining 13 bacteria between sample groups using unpaired
Kruskal-Wallis test with Bonferroni's multiple comparison. Post-hoc Wilcoxon test with Bonferroni-Dunn's
multiple comparison was performed to identify group-wise differences between Cancer – Non-cancer (#),
Cancer – Cancer-adjacent (*), Non-cancer – Cancer-adjacent (^).



Beta diversity (paired)

1134



1136 performed on Euclidean distance between each samples. No significant differences between cancer and cancer-

- 1137 adjacent tissue samples.
- 1138